Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update"

With great interest I read the recently published Assessment of Spondyloarthritis International Society (ASAS/European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of axial spondyloarthritis (axSpA,1), which included some but not many changes in comparison to the last recommendations.1 Let me first say that I largely agree with them. However, I would like to initiate a discussion related to the recommendation related to treatment with non-steroidal anti-inflammatory drugs (NSAIDs) in order to possibly change this recommendation in the next update. NSAIDs were clearly shown to work in axSpA including ankylosing spondylitis but a large proportion of patients does not tolerate this treatment for longer periods of time.2 3 All ASAS/EULAR recommendations for axSpA have included the recommendation to first start treatment with at least two NSAIDs within 4 weeks in patients with the correct diagnosis and high disease activity.1...
Source: Annals of the Rheumatic Diseases - Category: Rheumatology Authors: Tags: ARD Correspondence Source Type: research